TY - JOUR T1 - Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - 4669 AU - Paul Easton AU - Jenny Jagers AU - Michael Ji AU - Kurt Olson AU - Malcolm Johnson AU - Eric Wilde Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/4669.abstract N2 - Beta agonists have been shown to change ventilation and chest wall activity in COPD (Chest 2010 137:558-65). We studied the new ultra long acting beta2 agonist-steroid combination, vilanterol trifenatate/fluticasone furoate (Relvar, VFF) to determine its effects on breathing pattern, dyspnea and respiratory muscle function in severe COPD. We studied 6 subjects with severe COPD (mean FEV1 0.68), very minimally reversible, implanted with fine-wire EMG in parasternal (PARA) muscles, at baseline and 2hr after 2 puffs VFF. We measured: breathing pattern, dyspnea scores (BORG), PARA activity, sniff inspiratory nasal pressure (SNIP), and pulmonary function tests. Minute ventilation, frequency and mean inspiratory flow decreased (p<0.01). This breathing pattern was associated with much lower dyspnea scores (p<0.01). Mean PARA also decreased after VFF, while SNIP increased (p<0.01). We conclude that inhaled vilanterol trifenatate/fluticasone furoate (Relvar) induces a significant change in breathing pattern, which is associated with less dyspnea and increased global respiratory muscle function. ER -